Formulation Development
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
TCR2 Therapeutics Inc. recently announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo (nivolumab) and Yervoy (ipilimumab)…
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. recently announced the last participant has completed the 26-week dosing period and 30-day safety follow up visit in the GEM-3 study, Krystal’s…
Berkeley Lights Announces GSK Acquires Third Beacon Optofluidic System to Expand Antibody Therapeutics Development
Berkeley Lights, Inc. recently announced GlaxoSmithKline (GSK) has purchased an additional Beacon Optofluidic system to expand its antibody therapeutics capacity. The new Beacon system will….
Catalent's Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus Increases to $360 Million
Catalent recently announced a $230-million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene…
Micropore Appoints New Commercial Director
UK-based Micropore Technologies has recently appointed Denis Smit, Invista’s former Head of New Business Development, to the role of Commercial Director to lead their….
Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
Quris recently launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans – significantly improving efficacy and cutting drug development….
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Phathom Pharmaceuticals, Inc. recently announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating….
Menarini Group & Radius Health Announce Positive Phase 3 Topline Results From the EMERALD Trial Evaluating Elacestrant in Breast Cancer
The Menarini Group and Radius Health, Inc. recently announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a….
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc. recently announced it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease.…
HistoWiz Raises $32-Million Financing to Fully Automate Lab Operations, Launch New AI-Enabled Services & Establish a GLP Histopathology Lab in Miami
HistoWiz, a leading digital histopathology service company, recently announced the closing of a $32-million Series A financing. The company has provided automated histology for over…
Interpace Diagnostics Announces US Patent Approval: MicroRNAs as Biomarkers for Distinguishing Benign From Malignant Thyroid Neoplasms
Interpace Biosciences, Inc. recently announced the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for use of microRNAs…
MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-Resistant S. pseudintermedius
MatriSys Bioscience recently announced the publication of research on a strain of Staphylococcus felis (S. felis C4) isolated from feline skin for the treatment of Methicillin-resistant…
reMYND’s ReS19-T Program, Managing Calcium Homeostasis for Alzheimer’s, Has Moved to MAD Phase After Demonstrating Strong Safety in SAD Phase
reMYND NV recently announce it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in…
Pfizer & BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Pfizer Inc. and BioNTech SE recently announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of…
Silence Therapeutics Provides mRNAi GOLD Platform & Pipeline Updates
Silence Therapeutics plc, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with…
A New Study Using the SomaScan Platform Makes the Connection Between Genes & Proteins & Their Impact on Human Disease
In the largest proteogenomic study of its kind to date, an international research team led by scientists at the Berlin Institute of Health at Charité…
Ferrer & Treeway Enter License Agreement for the Development & Commercialization of TW001/FNP122 for Amyotrophic Lateral Sclerosis
Ferrer and Treeway recently announced they have entered into a licence agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic…
OliX Pharmaceuticals Enters Agreement With Pharmaron to Advance Non-Clinical Toxicology Testing for Hepatitis B Candidate
OliX Pharmaceuticals, Inc. recently announced it has selected Pharmaron, a leading contract research organization based in China, to conduct non-clinical toxicity studies to evaluate the…
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety & Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate
Emergent BioSolutions Inc. recently announced the first participant dosed in its pivotal Phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya…
